Periotherapia
Periotherapia is a venture company originating from Osaka University, dedicated to developing new treatments for intractable diseases such as treatment-resistant breast cancer. Founded in October 2017, the company focuses on drug discovery and clinical development, leveraging research on periostin variants. Their mission is to deliver innovative therapies to patients worldwide and contribute to solving social issues through expanding target diseases and developing drugs for various conditions.
Industries
Nr. of Employees
small (1-50)
Periotherapia
〒565-0871 Osaka, Yamadaoka 2-2, Suita City, Osaka Prefecture, Japan
Products
Clinical-stage investigational anti-target neutralizing antibody (clinical candidate)
Investigational monoclonal antibody developed to neutralize pathological protein splicing variants; advanced to clinical manufacturing and supplied for clinical studies targeting metastatic/recurrent HER2-negative breast cancer including triple-negative subtypes.
Clinical-stage investigational anti-target neutralizing antibody (clinical candidate)
Investigational monoclonal antibody developed to neutralize pathological protein splicing variants; advanced to clinical manufacturing and supplied for clinical studies targeting metastatic/recurrent HER2-negative breast cancer including triple-negative subtypes.
Services
Supply of clinical-stage investigational antibody to support investigator-led clinical studies, including coordination with trial sites.
Collaborative research agreements to investigate target biology, validate biomarkers and advance translational programs.
Supply of clinical-stage investigational antibody to support investigator-led clinical studies, including coordination with trial sites.
Collaborative research agreements to investigate target biology, validate biomarkers and advance translational programs.
Expertise Areas
- Therapeutic antibody development
- Splicing-variant biomarker discovery
- Preclinical safety and GLP toxicology
- Companion diagnostic development
Key Technologies
- Monoclonal antibody engineering
- Antibody humanization
- Splicing variant and biomarker analysis
- GLP toxicology studies